Sina Bavari, PhD

Sina Bavari is the executive vice president of infectious disease research and development at Tonix Pharmaceuticals. He is responsible for leading the development of Tonix’s infectious disease pipeline and serves as a key member of the Company’s executive leadership team. Bavari is based in Frederick, Maryland, and, as part of his role, oversees scientific development at Tonix’s Infectious Disease R&D Center (RDC) located there.

Bavari has a record of achievement utilizing new and complex technologies and in guiding programs through clinical decision points into advanced development. He has approximately 30 patents, has published over 300 peer-reviewed manuscripts, and has contributed to over 40 vaccine and therapeutic development candidates, as well as numerous Investigational New Drug candidate filings.

Most recently, he served as chief scientific officer/scientific director at the US Army Research Institute of Infectious Diseases (USAMRIID) and has held numerous leadership roles at USAMRIID, including chief, Molecular and Translational Sciences Division and Therapeutic Discovery Center; chief, Target Discovery & Experimental Microbiology, Integrated Toxicology Division; and chief, Immunology, Target Identification, and Translational Research, Bacteriology Division.

Bavari earned his PhD in immunotoxicology and pharmaceutical science at the University of Nebraska Medical Center in Omaha, Nebraska, and his MS in nuclear physics and nuclear pharmacy at the University of Southern California, Los Angeles.